StockData

Inogen vs InMode

INGN and INMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INGN and INMD compare

Inogen grew revenue faster over the last twelve months (13.7% versus −6.2% for InMode).

Inogen scores higher on the StockData Score (12 against 6 for InMode), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINGNINMD
Size and price
Market cap$151M–
Share price$5.69$13.27
Change, 1 year−19.7%−9.2%
Change, 5 years−82.8%−85.0%
Beta (5Y)1.251.43
Employees314660
StockData Score
Total score12 (better)6
Valuation score3 (better)0
Growth score1 (better)0
Performance score3 (better)1
Health score55
Dividend score00
Valuation
P/S0.4×–
P/B1.0×–
FCF yield−7.5%–
Fair value$17.93–
Margin of safety68.3%–
Growth
Revenue growth (TTM)13.7% (better)−6.2%
Revenue growth, 5Y average2.5%12.4% (better)
EPS growth (TTM)–−36.4%
EPS growth, 5Y average–9.9%
Profitability
Gross margin44.1%78.5% (better)
Operating margin−11.0%23.0% (better)
Net margin−9.3%–
FCF margin−3.0%22.7% (better)
Return on equity−20.0%–
Return on invested capital−49.2%25.1% (better)
Financial health
Debt / equity0.000.00
Current ratio2.969.88 (better)
Altman Z-score1.30–
Piotroski F-score5–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions72.9%49.5%
Held by insiders3.7%12.0%
Insider net buying, 12 months−$143K–
Short interest, % of float5.5%4.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.